Exposure to Phosphoglycerate Kinase 1 Activators and Incidence of Parkinson's Disease

Preclinical and epidemiological data suggest that phosphoglycerate kinase 1 activators could have neuroprotective properties and prevent PD.

[1]  D. Stone,et al.  Parkinson disease among patients treated for benign prostatic hyperplasia with α1 adrenergic receptor antagonists. , 2021, The Journal of clinical investigation.

[2]  N. Narayanan,et al.  Association of Glycolysis-Enhancing α-1 Blockers With Risk of Developing Parkinson Disease , 2021, JAMA neurology.

[3]  Alix M B Lacoste,et al.  Identifying drugs with disease-modifying potential in Parkinson's disease using artificial intelligence and pharmacoepidemiology. , 2020, Pharmacoepidemiology and drug safety.

[4]  T. Simuni.  Isradipine Versus Placebo in Early Parkinson Disease , 2020, Annals of Internal Medicine.

[5]  Philip M. Polgreen,et al.  Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases. , 2019, The Journal of clinical investigation.

[6]  Sebastian Heinzel,et al.  Update of the MDS research criteria for prodromal Parkinson's disease , 2019, Movement disorders : official journal of the Movement Disorder Society.

[7]  R. Wade-Martins,et al.  The Role of Astrocyte Dysfunction in Parkinson’s Disease Pathogenesis , 2017, Trends in Neurosciences.

[8]  A. Lees,et al.  Dysregulation of glucose metabolism is an early event in sporadic Parkinson's disease☆ , 2014, Neurobiology of Aging.

[9]  S. Goldman,et al.  Adrenoceptors in brain: Cellular gene expression and effects on astrocytic metabolism and [Ca2+]i , 2010, Neurochemistry International.

[10]  A. Schapira.  Mitochondria in the aetiology and pathogenesis of Parkinson's disease , 2008, The Lancet Neurology.

[11]  H. Braak,et al.  Parkinson's disease: a dual‐hit hypothesis , 2007, Neuropathology and applied neurobiology.

[12]  A. Schapira.  Mitochondrial dysfunction in Parkinson's disease , 2007, Cell Death and Differentiation.

[13]  M. Leon,et al.  Distribution and development of β‐adrenergic receptors in the rat olfactory bulb , 1995, The Journal of comparative neurology.

[14]  T. Hökfelt,et al.  Distribution of alpha 1 adrenoceptors in rat brain revealed by in situ hybridization experiments utilizing subtype-specific probes , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[15]  S. Hoyer.  Brain glucose and energy metabolism during normal aging , 1990, Aging.

[16]  C. Chapple.  A Comparison of Varying alpha-Blockers and Other Pharmacotherapy Options for Lower Urinary Tract Symptoms. , 2005, Reviews in urology.